Evidence map›Paper›PMID 34562515›Full record

ArticleJournal of virological methods2021

Increasing diagnostic possibilities using the geneLEAD VIII platform for detection of SARS-CoV-2.

Stefan A Boers, Bas C Mourik, Mario J A W M van Bussel, Caroline S de Brouwer, Els Wessels, Eric C J Claas

Abstract read
In one paragraph

Article in Journal of virological methods, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Stefan A BoersDepartment of Medical Microbiology, Leiden University Medical Center, 2300 RC, Leiden, the Netherlands. Electronic address: s.a.boers@lumc.nl.
Bas C MourikDepartment of Medical Microbiology, Leiden University Medical Center, 2300 RC, Leiden, the Netherlands.
Mario J A W M van BusselDepartment of Medical Microbiology, Leiden University Medical Center, 2300 RC, Leiden, the Netherlands.
Caroline S de BrouwerDepartment of Medical Microbiology, Leiden University Medical Center, 2300 RC, Leiden, the Netherlands.
Els WesselsDepartment of Medical Microbiology, Leiden University Medical Center, 2300 RC, Leiden, the Netherlands.
Eric C J ClaasDepartment of Medical Microbiology, Leiden University Medical Center, 2300 RC, Leiden, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At the time SARS-CoV-2 was identified as the cause of coronavirus disease 2019 (COVID-19) no in vitro diagnostic (IVD) tests were available since it was a new virus. Very shortly after the release of the genomic sequence of SARS-CoV-2, laboratory-developed tests (LDTs) were developed, made available and implemented in several laboratories in the Netherlands and globally. In this study, the performance of an E-gene Sarbeco specific real-time reverse-transcriptase PCR (RT-PCR) was verified on the open modus of the geneLEAD VIII sample-to-answer platform. The results obtained from 134 clinical samples, of which 63 had been tested positive, showed almost complete concordance compared to the same PCR on the routine diagnostic systems and that was validated according to the national reference standard. The only discordant sample tested positive using the routine diagnostic workflow with a cycle threshold (C

Indexed as

COVID-19SARS-CoV-2COVID-19 TestingHumansPoint-of-Care TestingReference StandardsSensitivity and SpecificityCOVID-19DiagnosisgeneLEADRapid diagnostic testRT-PCRSARS-CoV-2

Identifiers

PMID34562515
PMCPMC8457920

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.